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Objective: To evaluate blood banks in the Brazilian Amazon region with regard to structure
and procedures directed toward the prevention of transfusion-transmitted malaria (TTM).
Methods: This was a normative evaluation based on the Brazilian National Health Surveil-
lance Agency (ANVISA) Resolution RDC No. 153/2004. Ten blood banks were included in the
study and classiﬁed as ‘adequate’ (≥80 points), ‘partially adequate’ (from 50 to 80 points), or
‘inadequate’ (<50 points). The following components were evaluated: ‘donor education’ (5
points), ‘clinical screening’ (40 points), ‘laboratory screening’ (40 points) and ‘hemovigilance’
(15  points).
Results: The overall median score was 49.8 (minimum = 16; maximum = 78). Five blood banks
were  classiﬁed as ‘inadequate’ and ﬁve as ‘partially adequate’. The median clinical screening
score was 26 (minimum = 16; maximum = 32). The median laboratory screening score was
20  (minimum = 0; maximum = 32). Eight blood banks performed laboratory tests for malaria;
six tested all donations. Seven used thick smears, but only one performed this procedure
in  accordance with Ministry of Health requirements. One service had a Program of Exter-
nal  Quality Evaluation for malaria testing. With regard to hemovigilance, two  institutions
reported having procedures to detect cases of transfusion-transmitted malaria.
Conclusion: Malaria is neglected as a blood–borne disease in the blood banks of the Brazil-
ian  Amazon region. None of the institutions were classiﬁed as ‘adequate’ in the overall
classiﬁcation or with regard to clinical screening and laboratory screening. Blood bank pro-
fessionals, the Ministry of Health and Health Surveillance service managers need to pay
more  attention to this matter so that the safety procedures required by law are complied
with.
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alaria is endemic in the Brazilian Amazonian region and
s mainly transmitted by vectors. Transfusion-transmitted
alaria (TTM) is, however, one of the most important
lood–borne parasitic diseases and represents a signiﬁcant
isk for patients in endemic areas as cases are usually very
evere.1,2 In the United States, malaria is not endemic with
nly three TTM cases being reported on average per annum.2
n Brazil, the National Hemovigilance System, created in
002,3 has thus far registered four TTM cases, three in 2006 and
ne in 2007. By using nucleic acid tests (NAT) to detect Plas-
odium in endemic areas in Brazil, the prevalence of malaria
n eligible donors is estimated to be between 0.3% and 3%.4–6
t is therefore likely that TTM is underreported to the National
emovigilance System.
In Brazil, the Health Surveillance service (VISA) works to
ontrol transfusion risk and blood quality through actions
uch as standard regulations, inspection, health education
nd hemovigilance. These measures are carried out by VISA
t federal, state and municipal levels.7 The technical and san-
tary requirements for blood banks (BBs) to prevent TTM have
een deﬁned since 1988 by Law 7649/19888 and other regu-
ations – Decrees, Ministry of Health (MoH) Ordinances and
esolutions of the Collegiate Directorate (RDC) of the National
ealth Surveillance Agency (ANVISA).
In 1989, the MoH  Ordinance No. 721/GM/19899 introduced
he requirement for donor clinical and epidemiological
creening, including history of previous infections, recent
igns and symptoms and travel to endemic areas. During reg-
latory reviews, two substantial updates were included by
NVISA RDC No. 343/2002,10 namely: BBs in endemic areas
ust use the annual parasite index (API) to exclude donors
ho  visit high-risk areas (API >49.9 cases/1000 inhabitants)
nd must perform laboratory tests on eligible donors. All sub-
equent regulations have maintained these obligations with
mall modiﬁcations.
This study presents a normative evaluation of selected BBs
n the Brazilian Amazon region with the aim of preventing
Table 1 – Description of the model for classifying sectors/activit
evaluation.
Sector/activity Weight No. of items 
Education 0.5  1
Clinical screening 4  10
Laboratory screening 4 5
Hemovigilance 1.5 2
Final classiﬁcation – 18 1 4;3  6(6):394–402 395
TTM. The study’s objective was to analyze the adherence of
these BBs to prevailing regulations and standards, to describe
and discuss the current practices of these establishments and
to recommend measures to improve the prevention of TTM.
Methods
This was a normative evaluation study that focused on an
evaluation to inform management.11 According to Contan-
driopoulos et al.,12 to evaluate is to make a value judgment
about an intervention or its components in order to assist deci-
sion making. The judgment can be based on the application of
criteria and regulations and, in this case, it is called a normat-
ive evaluation. This, in turn, is deﬁned as the act of making a
judgment, comparing the organization (structure), the proce-
dure or methods developed (process), the resources deployed
and the results obtained with the requirements and criteria
established by regulations. It is a scientiﬁc activity that must
be carried out with methodological rigor.13
This study used external evaluators with the eval-
uation being performed in a natural context (without
interventions).12 The evaluation was based on ANVISA RDC
No. 153/200414 (RDC 153/2004), in force at the time, regarding
the issue of TTM prevention. The components evaluated were
structure and process.15
Data collection took place between January 2009 and June
2011. All nine Coordinator BBs responsible for the Brazilian
Amazon region and one hemotherapy nucleus were evalu-
ated. A standardized semi-structured list of questions was
used to collect data by interviewing the person technically
responsible for the BB and/or the person responsible for
the sectors/activities evaluated. Donor education, clinical
screening, laboratory screening and hemovigilance were eval-
uated. The interviews were conducted by just one researcher
with experience in administering inspection questionnaires
and epidemiology interviewing. In addition to the interview,
information was collected from educational materials for
donors and standards operational procedures (SOP).
The BBs were classiﬁed as adequate, partially adequate or
inadequate (Table 1), depending on the score obtained. The
ies and blood banks including scores obtained following
Score range Classiﬁcation
0  Inadequate
5 Adequate
0–20  Inadequate
>20–32 Partially adequate
>32–40 Adequate
0–20  Inadequate
>20–32 Partially adequate
>32–40 Adequate
0 Inadequate
7.5 Partially adequate
15 Adequate
0–50  Inadequate
form 50 to 80 Partially adequate
≥80 Adequate
oter.
donor and entitled ‘Care after donating blood’: ‘I have received396  rev bras hematol hem
concept of potential risk16 was deﬁned as ‘the possibility of the
occurrence of a disease, whilst not necessarily describing the
disease or the likelihood of its occurrence. This concept which
expresses the value judgment about potential exposure to a
possible risk was used to deﬁne the weighting of each activ-
ity and item. Different to epidemiological risk which can be
measured and calculated, potential risk is often determined
based on the cumulative perception of specialists regarding
the defects or faults in a given product, process or service over
time.16 The criteria for the scores were therefore based on the
authors’ assessment of the potential risk of TTM cases occur-
ring owing to non-compliance with the items of the norms.
Clinical and laboratory screening were considered to be criti-
cal for the regulation of TTM. The details of the scores for each
item are shown in Table 2. Although the criteria are based on
RDC 153/2004, the ﬁnal text of the criteria for each item eval-
uated expresses the speciﬁc focus on controlling the risk of
TTM. The criteria are not therefore literal transcriptions of the
requirements in RDC 153/2004.
The ideal model of best practices for ensuring maximum
TTM risk reduction, according to RDC 153/2004, is shown in
Table 3. In this model the four activities involved in TTM pre-
vention are shown as they relate to structures, processes and
results.
This study was approved by the Research Ethics Commit-
tees of the Júlio Müller University Hospital of the Universidade
Federal de Mato Grosso and the Medicine School of the Uni-
versidade de Brasília.
Results
The ﬁnal median score for the BBs as a whole was 49.8 (min-
imum = 16; maximum = 78) (Table 4). None of the BBs were
considered ‘Adequate’; ﬁve were classiﬁed as ‘Partially Ade-
quate’ and ﬁve as ‘Inadequate’. Table 5 provides detailed
results of the components and items.
With regard to the donor education component, all BBs only
used leaﬂets and posters to inform donors about blood–borne
diseases. Malaria was mentioned in leaﬂets in only two of
the ten BBs (Table 4). Four types of leaﬂets produced by the
MoH were found in two BBs, but none of them mentioned
TTM.
Six BBs were considered partially adequate and four
were considered inadequate in relation to clinical screening
(Table 4). Five BBs had SOPs for clinical screening of malaria but
only one used a standardized screening form containing all
the items required by the regulation to evaluate prior history
of malaria (fever, suspected malaria and have had malaria)
(Table 5).
Seven BBs used exclusion criteria in cases of exposure to
risk areas (Table 5) based on API rates and all of them deﬁned
high-risk areas as the municipal. One BB also took district
API rates into consideration when the municipal in question
was the state capital city. Four different ineligibility periods
were identiﬁed for donors who had traveled to high-risk areas,
namely 7 (1/7), 15 (1/7), 30 (2/7) and 180 (3/7) days. The Epi-
demiological Surveillance Service provides six of the ten BBs
with the API rates and one of the ten BBs directly accessed the
API rates in the Information System for Malaria in Endemic 2 0 1 4;3  6(6):394–402
Regions (SIVEP-Malaria). All of them used API for the preceding
year to deﬁne high-risk areas in the current year.
With regard to exclusion owing to prior history of malaria,
only one BB did not apply any of the criteria established by the
regulation and three applied all the required criteria (Table 5).
Nine BBs applied the criterion ‘had malaria in the last 12
months’, seven applied the criterion ‘fever in the last 30 days’
and three applied the criterion ‘suspected malaria in the last
30 days’. Two BBs used these last two criteria considering a
period of 15 days rather than 30. Other criteria mentioned were
‘having taken (or taking) medication for malaria’ (2 BBs) and
‘someone at home has got malaria’ (2 BBs).
Analysis of the screening form showed that only one BB
used a form containing the three exclusion criteria for prior
history of malaria, whilst two BBs had no question for these
criteria (Table 5). Considerable variations were observed in the
questions on the screening forms regarding having traveled
to and living in high-risk areas, namely: (1) ‘Have you been
in a high malaria risk area?’; (2) ‘Have you been in a high
malaria risk area? Where? How long ago?’; (3) ‘Have you trav-
eled to a different municipality within the state? When and
which one?’; (4) ‘Have you traveled anywhere in the last six
months? If yes, where?’; (5) ‘Do you come from an endemic
malaria zone?’; (6) ‘Have you been in an endemic malaria
region in the last 30 days?’; (7) ‘Do you live in a high malaria
risk area?’; and (8) ‘Do you live in a high malaria risk area?
Where? For how long?’. With the exception of questions 3
and 4, it is possible to interpret that the responsibility for
indicating exposure to malaria risk areas was placed on the
donor.
In relation to laboratory screening for malaria, four BBs
were classiﬁed as partially adequate and seven as inadequate
(Table 4). Only six BBs performed laboratory screening on all
donations in accordance with the regulation requirements
(Table 5). Two BBs only tested donors exposed to areas with
API between 10.0 and 49.9 cases per 1000 inhabitants (medium
risk) and a further two did not perform any test at all, arguing
that they were not in the endemic area. Seven BBs used thick
smears in laboratory screening and one used immunochro-
matographic testing. With regard to SOPs for the performance
of laboratory tests (thick blood smear or immunochromato-
graphic tests), two BBs were considered to have adequate
instructions. One of them performed thick blood smear testing
and the instructions adequately stated that 200 ﬁelds should
be evaluated before establishing a negative result.17
When considering the eight BBs that performed some type
of laboratory test for malaria (whether or not it complied
adequately with the regulations), six reported not having iden-
tiﬁed any positive tests in the last ﬁve years. Furthermore,
only one BB reported having a malaria test External Qual-
ity Evaluation Program (EQE) (Table 5). On the other hand, all
the participating BBs had EQE for the remaining laboratory
screening tests and for immunohematology.
With regard to the hemovigilance component, an innova-
tive experiment was encountered in one BB with the inclusion
of the following text in the information leaﬂet given to eachguidance that if I have symptoms of malaria/dengue and/or
fever within days of donating blood, I must inform the
Blood Bank by calling (telephone number) ’.
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Table 2 – Details of the criteria assessed for each blood bank sector and activity, their scores and the RDC 153/2004 item
used as a basis for the requirement.
Sector/activity Item evaluated Score RDC 153/2004 item
Donor education Provide educational materials to donors containing
information about transfusion-transmitted malaria.
10.0  B.4
Clinical screening
Interview the donor individually in a private place. 1.0 B.2 and B.5
Have standards operational procedures for clinical
screening of donors containing malaria exclusion
criteria.
1.0  A.11, B.5.2.6.2 and P.1
Use the criterion of travel to risk area to reject
donations, i.e. reject candidates coming from high
malaria risk areas as per API.
1.0  B.5.2.6.2
Use the criterion of living in a risk area to reject
donations, i.e. reject candidates living in high-risk areas
as per API.
1.0  B.5.2.6.2
Use the criterion of prior history of malaria to reject
donations, i.e.: (a) Reject candidates who have had
malaria in the 12 months prior to donation; (b) Reject
candidates who have had fever in the last 30 days; (c)
Reject candidates who have had suspected malaria in
the last 30 days.
None  = 0
1–2 = 0.5
3 = 1.0
B.5.2.6.2
Have a training program that has clinical screening for
malaria as part of its contents.
1.0  P.2
Use a standardized screening form (questionnaire) that
assesses travel to risk areas.
1.0  A.12, B.5.2.6.2 and B.6.4
Use a standardized screening form (questionnaire) that
assesses living in a risk area.
1.0  A.12, B.5.2.6.2 and B.6.4
Use a standardized screening form (questionnaire) that
assesses prior history of malaria.
– malaria 12 months prior to donation;
– fever in the last 30 days;
– suspected malaria in the last 30 days.
None = 0
1–2 = 0.5
3 = 1.0
A.12, B.5.2.6.2 and B.6.4
Existence of a warning mechanism capable of
preventing donation by donor who is ineligible owing to
risk of malaria, as per the criteria used by the blood
bank.
1.0 N.3 and N.6.f
Laboratory screening
Perform laboratory screening on all donors, as required
by RDC 153, i.e. perform parasite testing on all donors
living in or who have traveled to areas with medium or
low API, i.e. API <50.
4.0  B.5.2.6.2
Have written procedures for test performance in
accordance with the following references:
– Thick smear: as per Ministry of Health Malaria
Diagnosis Manual.
– Immunoenzymatic test: as per the manufacturer’s
instructions.
2.0  A.11 and P.1
Having a training program on the performance of
laboratory tests.
1.0  P.2
Have written procedures for test performance in
accordance with the following references:
– Thick smear: the Ministry of Health Malaria Diagnosis
Manual recommends that a negative result be given
after at least 200 ﬁelds have been evaluated.
– Immunoenzymatic test: as per the manufacturer’s
instructions.
2.0  A.11 and P.1
Have an External Quality Evaluation program for
malaria testing.
1.0  A.14
Hemovigilance
Have procedures to detect donors who have suspected
or conﬁrmed malaria following donation.
5.0  A.10
Have procedures to detect recipients suspected of
having malaria transmitted by blood products produced
by the service.
5.0  A.11 and A.17
API: annual parasite index.
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Table 3 – The ideal model of best practices to ensure maximum reduction of transfusion-transmitted malaria risk
according to RDC 153/2004.
Blood banks in malaria endemic areas
Activities to prevent transfusion-transmitted malaria
Education Clinical screening Laboratory screening Surveillance
Structures
Professionals trained and
educational material available to
clearly inform donors of the risk
to blood recipients becoming
infected with malaria through
transfusions
Professionals trained and
material available to
evaluate the risk of donors
being infected with
Plasmodium (written
instructions, up-to-date API
chart, standardized forms)
Professionals trained and
material available to
perform laboratory tests
(adequate algorithms,
written instructions,
external quality evaluation,
standardized forms)
Professionals trained and
material available to
identify and investigate
suspected TTM cases and
detect suspected malaria
cases following donation
(case deﬁnition,
standardized forms,
ﬂowcharts)
Processes
Donors receive educational
materials and guidance on their
contents
Donors adequately
assessed regarding: (a)
Traveling to areas with API
> 49; (b) Living in areas with
API > 49; (c) Prior history of
malaria
All  donors not excluded
during clinical screening
have blood sample tested
for the presence of the 3
Plasmodium species
prevalent in Brazil, as per
written instructions
All  suspected TTM cases
are investigated adequately
Blood banks are informed
of any donors suspected of
having malaria following
donation
Intermediate results
Donors understand the risks and
are sufﬁciently aware to be able to
answer clinical screening questions
adequately and honestly and are
proactive in providing information
Donors at increased risk
according to the
established criteria are
prevented from donating
Plasmodium-infected
donors are identiﬁed and
the blood products are
discarded
TTM investigation is
completed and positive
cases ate treated
Donors are informed of
their test results and
referred for a doctor’s
appointment
Donors suspected of having
malaria following donation
are detected and blood
products are discarded
Final results
Maximum reduction in the
number of contaminated blood
products available for
therapeutic use
Maximum reduction in the
number of TTM cases
No TTM related mortality
among recipients
TTM: transfusion-transmitted malaria; API: annual parasite index.
Table 4 – Final score obtained by each sector/activity and classiﬁcation of the ten blood banks according to the criteria
established in this evaluation.
Sector/activity Weighted scores for blood banks Median
A B C D E F G H I J
Education 0.0 5.0 0.0 0.0 0.0 0.0 0.0 5.0 0.0 0.0 0.0
Classiﬁcation I A I I I I I A I I
Clinical screening 28.0 26.0 24.0 20.0 16.0 26.0 32.0 32.0 16.0 30.0 26.0
Classiﬁcation PA PA PA I I PA I PA I PA
Laboratory screening 20.0 32.0 0.0 28.0 28.0 28.0 8.0 20.0 0.0 8.0 20.0
Classiﬁcation I PA I PA PA PA I I I I
Hemovigilance 0.0 15.0 0.0 0.0 7.5 0.0 0.0 0.0 0.0 7.5 0.0
Classiﬁcation I A I I PA I I I I PA
Maximum score 100 100 100 100 100 100 100 100 100 88.0a –
Score obtained 48.0 78.0 24.0 48.0 51.5 54.0 40.0 57.0 16.0 51.7 49.8
Final classiﬁcation I PA I I PA PA I PA I PA
I: inadequate; PA: partially adequate; A: adequate.
a Two laboratory screening items were not evaluated because they were outsourced activities.
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Table 5 – Scores obtained for each item evaluated at the ten blood banks studied (A–J) in the Brazilian Amazon region.
Sector/activity Item evaluated Blood banks na
A B C D E F G H I J
Donor education Provide educational
material to donors
containing information
about the risk of malaria
transmission
0.0 10 0.0 0.0 0.0 0.0 0.0 10 0.0 0.0 2
Subtotal 0.0 10 0.0 0.0 0.0 0.0 0.0 10 0.0 0.0
Clinical screening Interview the donor
individually in a private
place
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 10
Have SOP for clinical
screening of donors
containing malaria
exclusion criteria
1.0  0.0 0.0 0.0 0.0 0.0 1.0 1.0 1.0 1.0 5
Use the criterion of travel to
risk area to reject donations
1.0 0.0 1.0 1.0 0.0 1.0 1.0 1.0 0.0 1.0 7
Use the criterion of living in
a risk area to reject
donations
1.0  0.0 1.0 0.0 0.0 1.0 1.0 0.0 0.0 1.0 5
Use the criterion of prior
history of malaria to reject
donations
0.5 1.0 0.5 0.5 0.5 1.0 1.0 0.5 0.0 0.5 3
Have a training program
that has clinical screening
for malaria as part of its
contents
1.0 1.0 0.0 0.0 1.0 0.0 0.0 1.0 1.0 1.0 6
Use a standardized
screening form
(questionnaire) that
assesses travel to risk areas
0.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.0 1.0 8
Use a standardized
screening form
(questionnaire) that
assesses living in a risk area
0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 2
Use a standardized
screening form
(questionnaire) that
assesses prior history of
malaria
0.5 0.5 0.5 0.5 0.5 0.5 1.0 0.5 0.0 0.0 1
Existence of a warning
mechanism capable of
preventing donation by
donor who is ineligible
owing to risk of malaria, as
per the criteria used by the
blood bank
1.0  1.0 1.0 1.0 0.0 1.0 1.0 1.0 1.0 1.0 9
Subtotal 7.0 6.5 6.0 5.0 4.0 6.5 8.0 8.0 4.0 7.5
Laboratory screening Perform laboratory
screening on all donors as
required by RDC 153
4.0 4.0 0.0 4.0 4.0 4.0 0.0 4.0 0.0 0.0 6
Have written procedures for
test performance in
accordance with the
following references:
– Thick smear: as per
Ministry of Health Malaria
Diagnosis Manual.
– Immunoenzymatic test:
as per the manufacturer’s
instructions
0.0 0.0 0.0 2.0 2.0 2.0 0.0 0.0 0.0 2.0 4
Having a training program
on the performance of
laboratory tests
1.0  1.0 0.0 1.0 1.0 1.0 0.0 1.0 0.0 b 6
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Table 5 – (Continued)
Sector/activity Item evaluated Blood banks na
A B C D E F G H I J
Have written procedures to
test performance in
accordance with the
following references:
– Thick smear: the Ministry
of Health Malaria Diagnosis
Manual recommends that a
negative result be given
after at least 200 ﬁelds have
been evaluated
– Immunoenzymatic test:
as per the manufacturer’s
instructions
0.0 2.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 b 2
Have an External Quality
Control program
(Proﬁciency) for malaria
testing
0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1
Subtotal 5.0 8.0 0.0 7.0 7.0 7.0 2.0 5.0 0.0 2.0
Hemovigilance Have procedures to detect
donors who have suspected
or conﬁrmed malaria
following donation
0.0 5.0  0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 2
Have procedures to detect
recipients suspected of
having malaria transmitted
by blood products produced
by the service
0.0  5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 2
Subtotal 0.0 10 0.0 0.0 5.0 0.0 0.0 0.0 0.0 5.0
a Number of blood banks adequately complying with the item.
b Not evaluated because these are outsourced activities.Two BBs reported having detected cases of TTM resulting
from blood products produced by them. All these cases died.
Discussion
Publications about the evaluation of Brazilian BBs are rare and,
when they are found, their themes are donor satisfaction,18
serological test performance19 or costs.20 This is the ﬁrst
Brazilian study to evaluate the quality of the procedures and
methods used by BBs to prevent TTM.
Overall performance registered by the study shows that
adherence to RDC 153/2004 with regard to the prevention of
TTM is neglected by the participating BBs. Only one establish-
ment obtained more  than 60 points on the proposed scoring
system.
Donor education is an important factor for reducing
serological ineligibility and disease transmission through
transfusions.21 Although the participating BBs used leaﬂets
as an initiative aimed at donor education, most of the leaﬂets
made no reference to TTM. This strengthens the argument
that malaria is usually neglected as a risk for patients. More-
over, the effectiveness of using leaﬂets to educate donors
appears to be minimal. One study showed that educational
leaﬂets had a limited effect to reduce serological ineligibilityowing to HIV when used in isolation.22 Other educational
approaches therefore need to be encouraged.
Clinical screening was also identiﬁed as a weak point. This
stage is the ﬁrst step in ensuring safe blood and should be
performed by trained and competent personnel, using a pre-
deﬁned, validated and standardized questionnaire.23 Clinical
screening is even more  important for preventing TTM as the
sensitivity of the laboratory screening tests used is not high.24
The variation in the questions found in the screening ques-
tionnaires shows that there is no standardization among the
participating BBs to assess donors in relation to malaria. Stud-
ies to validate questions posed to donors with the aim of
preventing TTM need to be conducted.
With regard to the selection criteria regarding donors
exposed to risk areas, the regulations clearly need improve-
ments. In 1999 Kiesslich et al.25 proposed that API ranges
should be used as a parameter for TTM risk assessment. The
adopted API grades of risk (low, medium and high risk) have
not been created or standardized to achieve this objective.
There is no epidemiological data in the literature that enables,
a priori, API grades to be established for screening donors and
their use needs to be reassessed. We suggest that panel ses-
sions should be held with specialists to deﬁne the utility of
API as a parameter for donor selection. In the meantime, it
is essential that BBs have access to monthly API data so that
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linical screening can be performed based on current infor-
ation and not on information from the previous year, as was
he case with the BBs in this study.
Laboratory screening for malaria revealed relevant short-
omings, such as not testing all donors, the absence of EQE
or malaria tests and, in the case of the thick blood smear test,
n insufﬁcient number of ﬁelds were inspected (less than 200)
o conclude that the slides were free of Plasmodium.
The thick blood smear test has limited sensitivity to detect
symptomatic infections with low parasitemia.24 It must
herefore be used with great caution so as to reduce false neg-
tive results as far as possible. Since 2001 the MoH  has offered
 free EQE program for public BBs that includes serological and
mmunohematological tests. However, malaria has never been
ncluded in this program and its inclusion with regard to thick
lood smear testing has shown to be relevant.
Screening for malaria in BBs is a worldwide challenge. In
on-endemic countries, in general, the option is made to tem-
orarily exclude donors who have traveled to endemic regions
nd laboratory tests to directly detect the parasite are not
erformed. In endemic countries consensus does not exist
s to best practices to prevent TTM. Some countries with
ndemic areas, such as Colombia26 and Ethiopia,27 do not
se laboratory screening and undertake risk assessment and
election based exclusively on the epidemiological question-
aire. In Turkey,28 selection is done via a questionnaire and,
f donors are found to be ineligible, serological and molecular
ests can be used to reduce the period of ineligibility, as rec-
mmended by European guidelines. As such, we recommend
n evaluation as to the possibility of municipals or micro-
egions where native cases of malaria have not be recorded
or a long time using the same selection criteria as municipals
n non-endemic areas. This change would reduce the costs of
aboratory screening for malaria, although there might be a
ossible increase in clinical ineligibility.
Considering the limitations of thick smears as a screening
est in BBs, together with the possibility of reducing the num-
er of BBs obliged to perform laboratory screening for malaria,
e  suggest that the cost effectiveness of implanting NAT
or Plasmodium species in BBs in endemic municipalities or
icro-regions should be evaluated.
The weaknesses found in the process of selecting and iden-
ifying donors at risk of TTM indicate the importance of a
ensitive and structured hemovigilance system. It is impor-
ant that donors let BBs know if they have acquired malaria
r are suspected of having malaria after donation. Whether
r not donors take this initiative depends on them knowing
hat malaria can be transmitted through transfusions, and
n effective communication channels with BBs. The inclusion
n the SIVEP-Malaria notiﬁcation form of a question ‘Have
ou donated blood in the last 30 days?’, and an informa-
ion ﬂow between the notifying unit and BBs, could identify
onations made during the disease incubation period, thereby
educing TTM cases or enabling timely TTM identiﬁcation and
reatment, reducing its lethality. Nevertheless, asymptomatic
onors who  have malaria continue to be a challenge for BBs
nd hemovigilance has become an essential mainstay for early
TM case identiﬁcation.
This study has some methodological limitations worthy
f mention. The study’s design is cross-sectional and the 1 4;3  6(6):394–402 401
situation analyzed may have changed following it, possibly
as a consequence of the intervention used for this the study.
Moreover, the evaluation used a regulation that was revoked
during the course of the study. Nevertheless, the alterations
contained in the new regulations (ANVISA Resolution RDC
57/2010 and MoH Ordinance 2712/2013) were minimal with
regard to screening donors for malaria in endemic areas, such
as (i) municipalities where donors live or have traveled was
deﬁned as the API assessment area, (ii) deﬁnition of ineligi-
bility periods in cases of having traveled to high-risk areas
and (iii) permission to use laboratory tests that detect Plas-
modium antigens. These alterations do not alter the scores
and the classiﬁcations obtained in this study. Moreover, all
information received was self-reported and the answers
were conﬁrmed, whenever possible, by documents. However,
as it was an external evaluation, despite the people legally
responsible for the establishments agreeing to take part in
the study, at times access was not authorized to SOPs and,
in these cases, measures were not adopted to conﬁrm the
answers via a different means of veriﬁcation. This situation
was rare however (2 cases). As a general rule, the person
in charge of the sector was consulted in order to obtain
more precise answers regarding the practice in question. If
this person was not available, then the person technically
responsible for the BB answered the questionnaire (1 case).
As such, veriﬁcation errors may have occurred in some cases.
With regard to the scores, we emphasize that the weight
used for each question was decided by the researchers based
on arbitrary criteria as to the relevance of the question for
the potential risk of TTM occurrence. Other scoring systems
could have generated different ﬁnal classiﬁcation results.
Nevertheless, the validation of such scoring and classiﬁcation
systems is limited by the small number of events.
Despite these limitations, the results of the logical frame-
work proposed are considered to have met  the objectives of
evaluating BB structure and processes and can be used for
internal evaluations and correction of activities. They can also
be used by VISA in support of its actions, in particular inspec-
tions.
Finally, underlining the relevance of this subject, it should
be noted that in 2004 the World Health Organization launched
the Global Patient Safety Challenge, which includes ‘blood
safety’ as one of its pillars. As such, programs are required
to be implanted that ensure accessibility of high quality and
safe blood to all those who really need it.29 Donor selection
and hemovigilance are key elements of this process. Trans-
mission of any disease represents a failure and best practices
must be adopted so that patients are not harmed by blood.
This includes taking care to ensure the prevention of TTM.
Conclusion
The study provides evidence that adherence to TTM pre-
vention regulations was neglected by the participating BBs.
None of the BBs obtained an ‘adequate’ classiﬁcation, either
for the overall classiﬁcation or for the clinical or laboratory
screening components. BB professionals, MoH and VISA man-
agers need to pay greater attention to this matter so that
the safety procedures required by the standards are complied
oter.
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with, in particular the preparation of and compliance with
SOPs for clinical and laboratory screening of malaria, the inclu-
sion of malaria detection EQE and the implementation of the
hemovigilance system. In addition, we believe that these reg-
ulations, even after the 2010 and 2013 revisions, can be further
improved.
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